-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*It is only for medical professionals to read and refer to the domestic trastuzumab with "small specifications and multiple combinations, ready to use" has come out! "Small-size multi-combination" helps the new concept of trastuzumab ready-to-use, reducing the waste of residual fluid while not reducing the efficacy, and bringing patients a better medication experience
.
As the world's largest cancer, breast cancer is a serious threat to the health of women in our country
.
Among them, patients with HER2-positive breast cancer have the worst prognosis.
Such patients have rapid disease progression and are prone to relapse
.
Fortunately, with the application of trastuzumab, the survival of HER2-positive breast cancer has been significantly improved in recent years
.
The concept of whole-course management has important guiding significance for the treatment of anti-HER2 breast cancer.
However, due to the large number of patients, long course of disease, and long nursing cycle, "surplus fluid management" once became the most troublesome problem for nursing workers in the whole management process
.
In this regard, we specially invited Liu Ye, the head nurse of the Breast Surgery Department of the First Affiliated Hospital of China Medical University, to answer us how to solve the "surplus fluid management" in the whole management process of breast cancer anti-HER2 treatment
.
In the current epidemic situation, "remaining fluid management" has become the "soft underbelly" of anti-HER2 breast cancer treatment.
Head Nurse Liu Ye said, "The specification of the original trastuzumab is 440mg/bottle, and the remaining fluid after each use needs to be at 2℃~ Long-term storage at 8°C for the next use within 28 days
.
During this period, nurses need to check the remaining fluid every day
.
"Currently, the high-load state of nursing work is normal, but "remaining fluid management" is in basic diagnosis, treatment, and nursing care.
On the basis of, medication, dressing change, etc.
, the workload of nurses is further increased
.
At the same time, due to the continuation and recurrence of the new crown epidemic, many hospitals and wards have implemented closed management, resulting in patients not being able to come to the hospital to use drugs as scheduled
.
This increases the patient's troubles in carrying, transporting, and storing residual fluid, and even causes drug loss
.
In addition, based on the addition of preservatives, patients are also full of concerns about the safety of the original trastuzumab
.
Head Nurse Liu Ye said, “In this case, both nurses and patients are particularly looking forward to a small-sized, individually packaged, preservative-free trastuzumab
.
” Fortunately, in 2020, China’s independent research and development Trastuzumab (Hanquyou) 150mg was approved for marketing and entered the medical insurance in the same year
.
This year, the small size of 60mg has also been approved by the National Medical Products Administration (NMPA)
.
"Small-sized multi-combination" helps the new concept of trastuzumab ready-to-use, and brings patients a better medication experience.
Domestic trastuzumab includes two specifications of 150mg and 60mg, and the accurate dosage can be calculated according to the patient's weight.
Better satisfy Asian women
.
At the same time, it does not contain preservatives, it is ready to use, no residual liquid management is required, and the storage, transportation and management of preservative-containing drugs are eliminated
.
The flexible drug delivery method of "small specifications and multiple combinations" allows medical staff to see the light, and helps medical staff to devote themselves to the entire management and care of breast cancer patients, so that patients can achieve better cures and achieve better survival
.
Head Nurse Liu Ye hopes that Chinese pharmaceutical companies can launch more new products in the future to reduce the workload of clinical care workers, save patient costs, reduce patient worries, and meet medical insurance standards
.
Bring new treatment options for the majority of patients, and promote the chronic management of breast cancer diagnosis and treatment in China
.
Expert profile Liu Ye, the head nurse of the First Ward of Breast Surgery, the First Affiliated Hospital of China Medical University.
In 2014, he served as a health consultant in the field of breast cancer in the Cancer Care Project of China Soong Ching Ling Foundation.
Since 2014, he has served as the “PICC Technical Training Class” of the National Nursing Training Center of China Medical University.
"Infusion Port Technology Training Course" Professional Lecturer, Deputy Leader of the Rehabilitation Group of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association Deputy Chairman of the Youth Committee of the Nursing Group of the Chinese Anti-Cancer Association Rehabilitation Association, Liaoning Cell Biology Society, Breast Tumor Precision Treatment and Clinical Specialty Standing committee member of the Liaoning Provincial Life Sciences Society Breast Plastic Surgery, Reconstruction and Beauty Professional Committee Standing Committee member participated in the national key research and development plan digital diagnosis and treatment equipment research and development key special project, national natural and provincial natural subjects have successively presided over the school-level projects of China Medical University 3 published 8 papers in national journals and 4 SCI papers-End -*This information is for medical and scientific research reference only.
It is not recommended to use this product in any way that is inconsistent with the prescription information approved by your country.
.
As the world's largest cancer, breast cancer is a serious threat to the health of women in our country
.
Among them, patients with HER2-positive breast cancer have the worst prognosis.
Such patients have rapid disease progression and are prone to relapse
.
Fortunately, with the application of trastuzumab, the survival of HER2-positive breast cancer has been significantly improved in recent years
.
The concept of whole-course management has important guiding significance for the treatment of anti-HER2 breast cancer.
However, due to the large number of patients, long course of disease, and long nursing cycle, "surplus fluid management" once became the most troublesome problem for nursing workers in the whole management process
.
In this regard, we specially invited Liu Ye, the head nurse of the Breast Surgery Department of the First Affiliated Hospital of China Medical University, to answer us how to solve the "surplus fluid management" in the whole management process of breast cancer anti-HER2 treatment
.
In the current epidemic situation, "remaining fluid management" has become the "soft underbelly" of anti-HER2 breast cancer treatment.
Head Nurse Liu Ye said, "The specification of the original trastuzumab is 440mg/bottle, and the remaining fluid after each use needs to be at 2℃~ Long-term storage at 8°C for the next use within 28 days
.
During this period, nurses need to check the remaining fluid every day
.
"Currently, the high-load state of nursing work is normal, but "remaining fluid management" is in basic diagnosis, treatment, and nursing care.
On the basis of, medication, dressing change, etc.
, the workload of nurses is further increased
.
At the same time, due to the continuation and recurrence of the new crown epidemic, many hospitals and wards have implemented closed management, resulting in patients not being able to come to the hospital to use drugs as scheduled
.
This increases the patient's troubles in carrying, transporting, and storing residual fluid, and even causes drug loss
.
In addition, based on the addition of preservatives, patients are also full of concerns about the safety of the original trastuzumab
.
Head Nurse Liu Ye said, “In this case, both nurses and patients are particularly looking forward to a small-sized, individually packaged, preservative-free trastuzumab
.
” Fortunately, in 2020, China’s independent research and development Trastuzumab (Hanquyou) 150mg was approved for marketing and entered the medical insurance in the same year
.
This year, the small size of 60mg has also been approved by the National Medical Products Administration (NMPA)
.
"Small-sized multi-combination" helps the new concept of trastuzumab ready-to-use, and brings patients a better medication experience.
Domestic trastuzumab includes two specifications of 150mg and 60mg, and the accurate dosage can be calculated according to the patient's weight.
Better satisfy Asian women
.
At the same time, it does not contain preservatives, it is ready to use, no residual liquid management is required, and the storage, transportation and management of preservative-containing drugs are eliminated
.
The flexible drug delivery method of "small specifications and multiple combinations" allows medical staff to see the light, and helps medical staff to devote themselves to the entire management and care of breast cancer patients, so that patients can achieve better cures and achieve better survival
.
Head Nurse Liu Ye hopes that Chinese pharmaceutical companies can launch more new products in the future to reduce the workload of clinical care workers, save patient costs, reduce patient worries, and meet medical insurance standards
.
Bring new treatment options for the majority of patients, and promote the chronic management of breast cancer diagnosis and treatment in China
.
Expert profile Liu Ye, the head nurse of the First Ward of Breast Surgery, the First Affiliated Hospital of China Medical University.
In 2014, he served as a health consultant in the field of breast cancer in the Cancer Care Project of China Soong Ching Ling Foundation.
Since 2014, he has served as the “PICC Technical Training Class” of the National Nursing Training Center of China Medical University.
"Infusion Port Technology Training Course" Professional Lecturer, Deputy Leader of the Rehabilitation Group of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association Deputy Chairman of the Youth Committee of the Nursing Group of the Chinese Anti-Cancer Association Rehabilitation Association, Liaoning Cell Biology Society, Breast Tumor Precision Treatment and Clinical Specialty Standing committee member of the Liaoning Provincial Life Sciences Society Breast Plastic Surgery, Reconstruction and Beauty Professional Committee Standing Committee member participated in the national key research and development plan digital diagnosis and treatment equipment research and development key special project, national natural and provincial natural subjects have successively presided over the school-level projects of China Medical University 3 published 8 papers in national journals and 4 SCI papers-End -*This information is for medical and scientific research reference only.
It is not recommended to use this product in any way that is inconsistent with the prescription information approved by your country.
